Biomea Fusion, Inc.

NASDAQ (USD): Biomea Fusion, Inc. (BMEA)

Last Price

6.53

Today's Change

-0.58 (8.15%)

Day's Change

6.48 - 7.11

Trading Volume

907,091

Profile
BMEA

Exchange:  NASDAQ Global Select NASDAQ Global Select

Currency:  USD USD

Sector:  Healthcare - Healthcare Healthcare - Healthcare

Industry: 

CEO:  Mr. Thomas Andrew Butler Mr. Thomas Andrew Butler

Full Time Employees:  107 107

IPO Date:  2021-04-16 2021-04-16

CIK:  0001840439 0001840439

ISIN:  US09077A1060 US09077A1060

CUSIP:  09077A106 09077A106

Beta:  -0.43 -0.43

Last Dividend:  0.00 0.00

Dcf Diff:  2.23 2.23

Dcf:  4.88 4.88

Description

Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.

Address

900 Middlefield Road,
Redwood City, CA 94063, US

650 980 9099

http://biomeafusion.com

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment